Drug Profile
Research programme: NLRP3 inflammasome inhibitors - Roche
Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Inflazome
- Developer Roche
- Class Anti-inflammatories; Small molecules
- Mechanism of Action NLRP3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation